Gugulipid for treating cognitive disorders

Abstract: The present invention provides new uses of Gugulipid, an ethyl acetate extract of the resin of the plant Comiphora wighitii , for controlling or preventing cognitive dysfunction, hyperglycemia and some infective conditions of the skin and a method of preparing Gugulipid by agitating the resin in shake flask assembly or sonicating assembly and preparing a solid or a creamy dosage forms.

Description: Field of Invention The present invention claims some new uses of Gugulipid, an ethyl acetate extract of the resin of the plant Comiphora wightii, commonly called gum guggulu. Methods for controlling or preventing cognitive dysfunction are disclosed. Background of the Invention: Ayurveda takes a holistic view of human disease. It views any disease as a dysfunction of the whole body rather than of a single organ or physiological process. Most of the Ayurvedic drugs therefore are likely to act on a number of dysfunctions of the body involving a number of organs and functions. Gugulipid, an ethylacetate soluble fraction of gum guggul, was developed as a hypolipidemic agent, based on the reference to the lipid lowering effect of guggul resin in Charak Samhita, a classic text of Ayurveda. Chemopharmacological investigation of this extract resulted in the characterization of guggulsterone [ cis -and trans -4 , 17 (20)-pregnadiene-3, 16-dione] as the major constituent. Apart from guggulsterone, other chemical constituents in the ethyl acetate soluble fraction added to and modulated the total activity. This fraction rather than pure guggulsterone was developed as a hypolipidemic drug and named gugulipid. As a follow up of the holistic view of Ayurveda of human disease, gugulipid was tested for other related and unrelated conditions / dysfunction and found to possess cognitive activities. These novel uses of gugulipid are now claimed. Prior art Guggul, highly valued in Indian system of medicine Ayurveda, is the gum resin exudate of a small tree Commiphora wightii belonging to the family Burseraceae. It is specially recommended for the treatment of obesity, lipid disorders and rheumatoid arthritis (Ayurvedic treatise: Sushruta, Vagabhatta). In Tibetan medicine, the plant ( C. Wighitii ) mixed with other herbs is used for skin diseases, anemia, edema, salivation and heaviness of stomach [Lama, S. and Santra, S.C., Sci. Cult. 45, 262 (1979)]. Modem pharmacological studies on the crude drug and some of its fractions have supported the claims of Ayurveda. The anti-arthritis and anti-inflammatory activities were confirmed by Gujral and co-workers [Gujral, M. L., Sareen, K., Tangri, K. K., Amma, M. K. P. and Roy, A. K. Ind. J. Physiol. Pharmacol. 4, 267 (1960)]. The hypolipidemic and anti-atherosclerotic activities reported by Dwarakanath and Satyawati. [Dwarakanath, C., and Satyawati, G. V. Ayurveda Pradeepika (Ceylon), 1, 69 (1970)]; Satyawati, G.V. in "Effect of an indigenous drug and disorders of lipid metabolism with special reference to atherosclerosis and obesity (Medoroga)", M.D. Thesis (Doctor of Ayurvedic Medicine), Banaras Hindu University, Varanasi, (1966)]. Later on, its ethyl acetate extract was developed by joint efforts of Malti-Chem Research Center, Baroda and Central Drug Research Institute, Lucknow as hypolipidemic drug [A process for obtaining hypolipidemic and anti-platelet aggregation fraction from guggul resin. Indian Patent No. 148265 dated 6.4.79., N. K. Kapoor., Sukh Dev and S. Nityanand]. A mixed type of mechanism has been implicated for lipid lowering effect of gugulipid. The stimulation of plasma LCAT, hepatic lipases, receptor mediated catabolism of LDL and increased faecal bile acid excretion as well as suppression of hepatic cholesterol biosynthesis are the mechanisms responsible for lipid lowering effect of gugulipid [S. Nityanand and N.K.Kapoor, Ind. J. Exp. Biol. 11, 395 (1973); N. K. Kapoor and S. Nityanand, Ind. J. Heart Res. Supp-1) 22 (1988)]. With the discovery of hypolipidemic activity of the gum. resin, systematic chemical investigations were carried out to characterize compounds of the gum resin responsible for hypolipidemic activity. Mc Cook et al. have recently claimed alcoholic extract of gum guggul for controlling or preventing sebum secretion from sebocytes which is associated with a shiny, undesirable appearance and a disagreeable tactile sensation [J.P. Mc Cook et. al. U.S. Patent 5,690,948 (1997). Antisebum and antioxidant compositions containing gugulipid and alcoholic fractions thereof]. The applicants have earlier obtained a US Patent No. 6086889 for a process for isolation of lipid fraction containing Z and E guggulsterones from the aerial parts of the plant Comiphora wighitii. The said process comprises the steps of soaking or soxhlet extracting the powdered aerial part of the plant with a non polar solvent; filtering or decanting the extract; soaking the material again in polar solvent; filtering and concentrating the extracted material in the polar solvent under reduced pressure and gel filtration or silica gel chromatography to obtain Z and E ketosteroid containing lipid fraction. The present invention introduces non-obvious modifications to the extraction method as described in the earlier prior art and describes new uses of the Gugulipid, which were not known earlier. Genesis of the Invention With the isolation of variety of compounds of varied structural classes such as lignans, lipids, diterpenoids and steroids, we initiated quite early a program to investigate structure based biological profiles of gugulipid. Earlier, it was revealed that the hypolipidemic and thyroid stimulating actions of guggulsterone [Tripathi, S. N., Gupta, M. Dwivedi, L. D. and Sen, S. P., J. Res. Ind. Med. 10, 11 (1975); Singh, V. and Kapoor, N. K. in "Stimulation of low density lipoprotein receptors activity in liver membrane of guggulsterone treated rats." In Proceedings of Society of Biological Chemists, India, 57th Annual Meeting, CSIR Center for Biochemicals, New Delhi, October 9-12, 1988]. Role in improving cognitive functions Recent developments in understanding of neurosteroids, role of free radicals and antioxidants in brain function as well as in hyperglycemia prompted us to explore gugulipid for these activities. Behavioral studies have suggested a potential role of pregnenolone, in particular, for memory enhancement. Intracerebroventricular (i.c.v.) administration of pregnenolone and pregnenolone sulfate leads to an amelioration in various memory task in rodents [Flood, J. F., Morley, J. F., and Robert, E., Memory enhancing effects in male mice of pregnenolone and of steroids metabolically derived from it; Proc. Natl. Acad. Sci. USA; 89, 1567 (1992)]. These memory-enhancing effects might be attributed to the N-methyl-D-aspartate (NMDA)-antagonistic properties of pregnenolone sulfate since NMDA agonists have been shown to impair cognitive functions in rodents [Bowlby, M. R., Pregnenolone sulfate potentiation of N-methyl-D-aspartate receptor channels in hippocampal neurons. Mol. Pharmacol., 43, 813 (1993)]. As already stated, cholesterol is the precursor of neurosteroid pregnenolone. These findings prompted us to explore memory enhancing properties of gugulipid because of similarity among biogenic precursor of pregnenolone (1) and steroids present in Gugulipid such as guggulsterol- I (2), guggulsterol- II (3) and guggulsterol-III (4) (Fig-1) [V. D. Patil, U.R.Nayak and Sukh Dev: Chemistry of Ayurvedic Crude Drugs -I, Tetrahedron 28, 2341 (1972)]. Objects of the present invention An object of the present invention was to develop cognition enhancing effect of gugulipid orally in any pharmaceutical preparations. Summary of the invention The present invention provides use of gugulipid (an ethyl acetate extract of gum or resin from the tree Comiphora wightii ) in the manufacture of an agent for reducing, controlling or preventing cognitive dysfunction in a mammal. The gugulipid may be in any form, in particular, in the form of an extract, solid dosage or cream formulation. The use of gugulipids enables cognitive behaviour to be enhanced by preferably administering gugulipid as an extract or by mixing with other pharmaceutically acceptable additives before administration. The use of the gugulipid is for the manufacture of an agent. The agent may include any further additive, suitable additives being one or more selected from a protein, carbohydrate, sugar, talc, magnesium stearate, microcrystalline cellulose, starch, calcium carbonate and/or any other pharmaceutically acceptable carrier. In the manufacture of the agent, a solid dosage may be obtained by maceration of the gugulipid compound with starch and microcrystalline cellulose together in a mixture, to obtain a flowable powder. The solid dosage may be obtained in the form of a tablet by dissolving gugulipid in ethanol and adding starch and microcrystalline cellulose. This is followed by evaporating the solvent, passing the material through 40 mesh size sieve to obtain granules and compressing the granules to obtain a tablet. The use of gugulipid as per the invention may be for treating a patient suffering from a human memory dysfunction, such as Alzheimer's disease or Korsakoffs disease, optionally in combination with other treatments. The use may be for the reversal of Atropine inducing amnesia. The use may be such that the gugulipid, in any form, is administered at a dosage level equivalent to 40mg/kg/day, optionally for 7 days. Use may be such that the guglipid is administered at a dosage level of 100mg/kg of bodyweight per day. The use of gugulipid may be wherein the gugulipid is supplied as a cream of gugulipid 5% in polyethylene glycol (PEG). The cream is suitable for multiple applications, such as twice daily. Detailed description of the invention: Accordingly, the present invention provides gugulipid in combination with or associated with an additive is used for controlling or preventing cognitive dysfunction in mammals. In another embodiment of the invention, Gugulipid is administered in the form of extracts, solid dosages or cream formulations as may be suitable. In another embodiment of the invention, for enhancing cognitional behavior by feeding gugulipid or mixed with other agent of similar property given orally in the form of suitable pharmaceutical preparations and with amount necessary for activity. In another embodiment of the invention, for reversal of Atropine induced amnesia in male swiss mice by administrating gugulipid dosage equivalent to 40 mg/kg/day for about 7 days either in the form of extracts or solid dosage. In another embodiment of the invention, Gugulipid is used for treatment of patients suffering from human memory dysfunctions like Alzheimers disease and Korsakoff's disease alone or in combination with other treatments. The inventive methods of controlling memory dysfunction, employ gugulipid or extract of gum/resin in pharmaceutically acceptable dosage forms. Brief Description of Accompanying Drawings: Figure. 1 shows the structure of Cholesterol metabolite and related compounds in gugulipid. Figure. 2 shows the structure of Lignans from Commiphora mukul and Troglitazone with 1,2- or 1,4-bis-oxygenated phenyl pharmacophore. Figure. 3 shows the effect of Gugulipid and Ginkobyloba on Atropine induced dementia in passive avoidance test. The following example is given by the way of illustration and should not be construed to limit the scope of the present invention. Example I This example reports cognition enhancing property of gugulipid in animal model of Alzheimer's disease. Comparative study of Gugulipid and ginkgo biloba as cognitive enhancer by passive avoidance test. One of the most common tests in memory research is the inhibition to imitate activities or learned habits. The term "passive avoidance" is usually employed to describe experiments in which the animal learns to avoid a noxious event by suppressing a particular behavior. Different forms of human memory dysfunctions can be modeled in the animal by the administration of different centrally acting drugs to normal, healthy subjects. Anticholinergics like scopolamine or atropine produces transient amnestic effects similar to the deficits observed in the patients with Alzheimer's disease (AD), whereas benzodiazepines produce effects similar to the anterograde amnesia typical of patients with Korsakoff's disease (KD). Rationale of test procedure: When a mouse or rat is put in a closed chamber consisting of interconnected dark and lighted compartments, it prefers to be in dark near walls, but when given an electric shock in the dark compartment it moves to the lighted compartment and remains there till it remembers the danger. A typical paradigm of testing cognition behavior consist of three phases: Familiarization: the animal is placed in the lighted compartment and after 10 seconds of exploration, it returns to the home cage. Learning: Immediately after the animal has come to the dark room, an unavoidable foot shock is applied and the animals returned to the illuminated side. Retention test: 24 hr after the learning trial, the animal is again placed to the illuminated side after feeding test drug and the procedure of learning is repeated. The latency period is measured. Evaluation : the time of latency during the learning and retention test phase is measured. A prolongation of the latency period is defined as learning. Passive avoidance test: The mice were subjected to single trial passive avoidance test as described by Brioni et al [Brioni, J. D.; Hock, F. J. and McGaugh, J. J. in Drug Effects on Learning and Memory'. H. G. Vogel and W. H. Vogel (Eds.). Drug Discovery and Evaluation: Pharmacological Assays" Springer -Verlag. Berlin ,1997]. The passive avoidance test was studied by a computerized shuttle box (Columbus Instruments, Ohio, USA) provided with a software program PACS 30. The shuttle box is comprised of two compartments. An automated door was used to isolate the compartments. After an exploration period of 30 seconds for acclimatization, the animal was subjected to a trial of 270 seconds. Each mouse was placed in the bright (light intensity 10) compartment and on transfer into the dark compartment it was given an electric shock (0.5mA for 5 s) through a floor grid. The computerized door was set to close upon transfer, subjecting the mouse to the full duration of electric shock. Infrared sensors monitor the transfer from one compartment to another, which recorded as transfer latency time (TLT) in seconds. TLT was recorded in control and acute stress group (30 min after immobilization) on day 1 (trial I) and next day (trial II). In chronic stress group trial I was given 30 min after immobilization (day 5) and trial II 24 hrs later. The criterion for improved cognitive activity was taken as an increase in the TLT on trial II as compared to trial I. Procedure Effect of administration of gugulipid as Extract: Male Swiss mice (25-30 g) were randomized into 4 groups (n = 10). Extracts Gugulipid (40mg/kg/day.) and G. biloba (30 mg/kg/day.) were administered in one group each for 7 days, in the other two groups corresponding volume vehicle was administered. On the 8 th day atropine (4 mg/kg, imp.) was administered in each animal of extract treated and one vehicle group 5 min before Passive Avoidance Test in a computerized shuttle box using PACS-30 software. The transfer latency time (TLT) from illuminated chamber to the dark chamber was recorded in all the groups. Mean values and standard error (SE) of mean was calculated TLT (passive avoidance test) of each group. The significance of difference between the values of two groups was determined by Student's 't' test. Gugulipid is equally active to the standard drug G. biloba and the data is presented in bar diagram (Fig.3). The experiments were carried out according to the following protocol: EFFECTIVE Both the extract treated groups showed significant reversal of atropine induced amnesia. Effect of administration of solid dosage of Gugulipid: Gugulipid solid dosage form equivalent to 40mg/kg/day for 7 days was administered in swiss mice. It was found equally effective to the standard drug Ginkobiloba in passive avoidance test model. Solid dosage form was prepared by mixing gugulipid with starch or microcrystalline cellulose. It should be understood that the specific forms of the invention illustrated and described so far are intended to be representative only. The change, including but not limited to those suggested in this specification, may be made in the illustrated embodiments without departing from the clear teaching of the disclosure. Accordingly, reference should be made to the following appended claims in determining the full scope of the invention. Advantages of the Present Invention: The present invention provides new uses of Gugulipid for enhancement of cognition.

Claims: Use of gugulipid, an ethyl acetate extract of gum or resin from the tree Comiphora wightii, in the manufacture of an agent for reducing, controlling or preventing cognitive dysfunction, in a mammal. Use, as claimed in claim 1, wherein gugulipid is in the form of an extract, solid dosage or cream formulation. Use, as claimed in claim 1 or claim 2, wherein cognitional behavior is enhanced and wherein gugulipid is to be administered as an extract or mixing with other pharmaceutically acceptable additives. Use, as claimed in any one of claims 1 to 3, wherein the agent includes an additive, the additive being one or more selected from protein, carbohydrate, sugar, talc, magnesium stearate, microcrystalline cellulose, starch, calcium carbonate and/or a pharmaceutically acceptable carrier. Use, as claimed in any one of claims 1 to 4, wherein the solid dosage is obtained by maceration of the compound gugulipid, starch and microcrystalline cellulose in a mixture, to obtain a flowable powder. Use, as claimed in any one of claims 1 to 4, wherein the solid dosage in the form of a tablet is obtained by dissolving gugulipid with ethanol and adding starch and microcrystalline cellulose, evaporating the solvent, passing the material through 40 mesh size sieve to obtain granules and compressing the granules to obtain a tablet. Use, as claimed in any one of claims 1 to 6 for treating a patient suffering from a human memory dysfunction, such as Alzheimer's disease or Korsakoff's disease, optionally in combination with other treatments. Use, as claimed in any one of claims 1 to 7 for the reversal of Atropine induced amnesia. Use, as claimed in any one of claims 1 to 8, wherein the gugulipid is to be administered at a dosage level equivalent to 40mg/kg/day, optionally for 7 days. Use, as claimed in any one of claims 1 to 8, wherein the gugulipid is to be administered at a dosage level of 100mg/kg-body weight.

Inventors: ASTHANA ONKAR PRASAD, MURTHY PUVVADA SRI RAMCHANDRA, NAND NITYA, NATH CHANDESHWAR, PAL RAGHWENDRA, PRATAP RAM, RAINA DEEPAK, RASTOGI ANIL KUMAR, SHANKAR GIRJA, SINGH HEMANT KUMAR, SINGH NARENDRA, SINGH SATYAWAN, SRIVASTAVA ARWIND KUMAR, SRIVASTAVA SUDHIR, ASTHANA, ONKAR PRASAD, MURTHY, PUVVADA SRI RAMCHANDRA, NAND, NITYA, NATH, CHANDESHWAR, PAL, RAGHWENDRA, PRATAP, RAM, RAINA, DEEPAK, RASTOGI, ANIL KUMAR, SHANKAR, GIRJA, SINGH, HEMANT KUMAR, SINGH, NARENDRA, SINGH, SATYAWAN, SRIVASTAVA, ARWIND KUMAR, SRIVASTAVA, SUDHIR
Applicants: COUNCIL SCIENT IND RES, COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
Application year: 2001
Main classification: A61K35
IPC codes: A61K9, A61P37, A61P17, A61P31, A61K31, A61K47, A61K36, A61P3, A61P25, A61P29